Immune Checkpoint Inhibitors Market By Type (CTLA-4 inhibitor, PD-1 inhibitor, PD-L1 inhibitor), By Application (Lung Cancer, Bladder Cancer, Melanoma, Colorectal Cancer, Hodgkin lymphoma, Others): Global Opportunity Analysis and Industry Forecast, 2023-2

Immune Checkpoint Inhibitors Market By Type (CTLA-4 inhibitor, PD-1 inhibitor, PD-L1 inhibitor), By Application (Lung Cancer, Bladder Cancer, Melanoma, Colorectal Cancer, Hodgkin lymphoma, Others): Global Opportunity Analysis and Industry Forecast, 2023-2032


The immune checkpoint inhibitors market was valued for $40,126.30 million in 2022 and is estimated to reach $189,379.51 million by 2032, exhibiting a CAGR of 16.8% from 2023 to 2032. Immune checkpoint inhibitors represent a category of drugs utilized in cancer immunotherapy. They function by targeting specific proteins on immune or cancer cells, thereby boosting the body's immune response against cancer. While the immune system serves as a critical defense mechanism against abnormal or cancerous cells, certain mechanisms, known as immune checkpoints, regulate its function, preventing excessive attacks on healthy cells.  

Cancer cells exploit these checkpoints to evade the immune system's detection and destruction. Immune checkpoint inhibitors work by targeting and blocking specific proteins, such as PD-1 (programmed cell death protein 1), PD-L1 (programmed death-ligand 1), or CTLA-4 (cytotoxic T-lymphocyte-associated protein 4), which are involved in these checkpoints. By inhibiting these proteins, these drugs enable the immune system to more effectively identify and combat cancer cells.  

The major factors driving the growth of immune checkpoint inhibitors market are advancements in R&D, increase in prevalence of cancer cases, increase in number of clinical trials, expanding research initiatives, strategic collaborations, and growing approvals for new indications. Cancer remains a leading cause of mortality globally, with continuous rise in diagnosed cases across various cancer types. For instance, National Cancer Institute, Division of Cancer Control & Population Sciences (DCCPS), stated that, 623,405 people are living with metastatic breast, prostate, lung, colorectal cancer, or metastatic melanoma in the U.S. As the burden of cancer grows, there is a pressing need for more effective treatment options, leading to the heightened demand for immune checkpoint inhibitors.  

Further, increase in the number of clinical trials focusing on the immune checkpoint inhibitors is expected to fuel the market growth. There is a growing inclination among pharmaceutical companies, biotechnology firms, and academic institutions to allocate more resources toward clinical research. This investment aims to scrutinize the safety, effectiveness, and possible uses of immune checkpoint inhibitors across diverse cancer types. These trials, focused on investigating novel drug combinations, evaluating treatment reactions, and pinpointing predictive biomarkers, significantly contribute to broadening the comprehension of immune-driven treatments.  For instance, in July 2023, Merck & Co., Inc., and Moderna, Inc. announced the initiation of the pivotal Phase 3 randomized V940-001 clinical trial evaluating V940 (mRNA-4157), an investigational individualized neoantigen therapy (INT), in combination with KEYTRUDA, Merck’s anti-PD-1 therapy, as an adjuvant treatment in patients with resected high-risk (Stage IIB-IV) melanoma. The results from these trials not only drive drug development but also inform treatment decisions, further boosting the growth of the immune checkpoint inhibitors market.  

Furthermore, strategic collaborations among pharmaceutical companies, biotechnology firms, and academic institutions have emerged as a key factor propelling the growth of the immune checkpoint inhibitors market. Partnerships and alliances facilitate the consolidation of expertise, resources, and technologies, expediting the drug discovery and development process. For instance, in May 2020, Innovent Biologics, Inc., a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for the treatment of cancer, autoimmune, metabolic & other major diseases, and The University of Texas MD Anderson Cancer Center, announced a strategic collaboration agreement to co-develop TYVYT (sintilimab injection), Innovent’s anti-PD-1 monoclonal antibody, for treating rare cancers in the U.S. In addition, collaborative efforts facilitate the exploration of diverse therapeutic applications, the conduct of larger clinical trials, and the accelerated translation of research findings into clinical applications. Such collaborations have led to the successful development and commercialization of several immune checkpoint inhibitors, widening their reach and applications in oncology.  

The immune checkpoint inhibitors market is segmented on the basis of product type, application, and region. By product type, the market is categorized into CTLA-4 inhibitor, PD-1 inhibitor, and PD-L1 inhibitor. On the basis of application, the market is classified into lung cancer, bladder cancer, melanoma, colorectal cancer, Hodgkin lymphoma, and others. Region-wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, and rest of LAMEA).  

Major key players that operate in the global immune checkpoint inhibitors market are Merck & Co., Inc., AstraZeneca plc, F. Hoffmann-La Roche Ltd., Merck KGaA, Regeneron Pharmaceuticals, Inc., Bristol-Myers Squibb Company, BeiGene, Ltd., Shanghai Junshi Biosciences Co., Ltd., GlaxoSmithKline plc, and Innovent Biologics, Inc. The key players have adopted strategies such as acquisition, agreement, strategic alliance, collaboration, clinical trial, expansion, joint venture, new product development, and product approval to expand their product portfolio.

Key Benefits For Stakeholders

This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the immune checkpoint inhibitors market analysis from 2022 to 2032 to identify the prevailing immune checkpoint inhibitors market opportunities.
The market research is offered along with information related to key drivers, restraints, and opportunities.
Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
In-depth analysis of the immune checkpoint inhibitors market segmentation assists to determine the prevailing market opportunities.
Major countries in each region are mapped according to their revenue contribution to the global market.
Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
The report includes the analysis of the regional as well as global immune checkpoint inhibitors market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

By Type

CTLA-4 inhibitor
PD-1 inhibitor
PD-L1 inhibitor

By Application

Lung Cancer
Bladder Cancer
Melanoma
Colorectal Cancer
Hodgkin lymphoma
Others

By Region

North America
U.S.
Canada
Mexico
Europe
Germany
France
UK
Rest of Europe
Asia-Pacific
Japan
China
India
Australia
South Korea
Rest of Asia-Pacific
LAMEA
Brazil
Rest of LAMEA

Key Market Players

Merck & Co., Inc.
AstraZeneca plc
Merck KGaA
Bristol-Myers Squibb Company
BeiGene, Ltd.
Shanghai Junshi Biosciences Co., Ltd.
GlaxoSmithKline plc
Innovent Biologics, Inc.
F. Hoffmann-La Roche Ltd.
Regeneron Pharmaceuticals, Inc.

Please Note: It will take 7-10 business days to complete the report upon order confirmation. 


CHAPTER 1: INTRODUCTION
1.1. Report description
1.2. Key market segments
1.3. Key benefits to the stakeholders
1.4. Research methodology
1.4.1. Primary research
1.4.2. Secondary research
1.4.3. Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. CXO Perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top impacting factors
3.2.2. Top investment pockets
3.3. Porter’s five forces analysis
3.3.1. High bargaining power of suppliers
3.3.2. Moderate threat of new entrants
3.3.3. Low threat of substitutes
3.3.4. Low intensity of rivalry
3.3.5. High bargaining power of buyers
3.4. Market dynamics
3.4.1. Drivers
3.4.1.1. Increase in incidences of cancer across the globe
3.4.1.2. Rise in geriatric population
3.4.1.3. Supportive reimbursement policies for immune checkpoint inhibitors
3.4.2. Restraints
3.4.2.1. Higher cost of immune checkpoint inhibitors
3.4.3. Opportunities
3.4.3.1. Increase in number of pipeline drugs
3.4.3.2. Growth opportunities in emerging markets 
CHAPTER 4: IMMUNE CHECKPOINT INHIBITORS MARKET, BY TYPE
4.1. Overview
4.1.1. Market size and forecast
4.2. CTLA-4 inhibitor
4.2.1. Key market trends, growth factors and opportunities
4.2.2. Market size and forecast, by region
4.2.3. Market share analysis by country
4.3. PD-1 inhibitor
4.3.1. Key market trends, growth factors and opportunities
4.3.2. Market size and forecast, by region
4.3.3. Market share analysis by country
4.4. PD-L1 inhibitor
4.4.1. Key market trends, growth factors and opportunities
4.4.2. Market size and forecast, by region
4.4.3. Market share analysis by country
CHAPTER 5: IMMUNE CHECKPOINT INHIBITORS MARKET, BY APPLICATION
5.1. Overview
5.1.1. Market size and forecast
5.2. Lung Cancer
5.2.1. Key market trends, growth factors and opportunities
5.2.2. Market size and forecast, by region
5.2.3. Market share analysis by country
5.3. Bladder Cancer
5.3.1. Key market trends, growth factors and opportunities
5.3.2. Market size and forecast, by region
5.3.3. Market share analysis by country
5.4. Melanoma
5.4.1. Key market trends, growth factors and opportunities
5.4.2. Market size and forecast, by region
5.4.3. Market share analysis by country
5.5. Colorectal Cancer
5.5.1. Key market trends, growth factors and opportunities
5.5.2. Market size and forecast, by region
5.5.3. Market share analysis by country
5.6. Hodgkin lymphoma
5.6.1. Key market trends, growth factors and opportunities
5.6.2. Market size and forecast, by region
5.6.3. Market share analysis by country
5.7. Others
5.7.1. Key market trends, growth factors and opportunities
5.7.2. Market size and forecast, by region
5.7.3. Market share analysis by country
CHAPTER 6: IMMUNE CHECKPOINT INHIBITORS MARKET, BY REGION
6.1. Overview
6.1.1. Market size and forecast By Region
6.2. North America
6.2.1. Key market trends, growth factors and opportunities
6.2.2. Market size and forecast, by Type
6.2.3. Market size and forecast, by Application
6.2.4. Market size and forecast, by country
6.2.4.1. U.S.
6.2.4.1.1. Market size and forecast, by Type
6.2.4.1.2. Market size and forecast, by Application
6.2.4.2. Canada
6.2.4.2.1. Market size and forecast, by Type
6.2.4.2.2. Market size and forecast, by Application
6.2.4.3. Mexico
6.2.4.3.1. Market size and forecast, by Type
6.2.4.3.2. Market size and forecast, by Application
6.3. Europe
6.3.1. Key market trends, growth factors and opportunities
6.3.2. Market size and forecast, by Type
6.3.3. Market size and forecast, by Application
6.3.4. Market size and forecast, by country
6.3.4.1. Germany
6.3.4.1.1. Market size and forecast, by Type
6.3.4.1.2. Market size and forecast, by Application
6.3.4.2. France
6.3.4.2.1. Market size and forecast, by Type
6.3.4.2.2. Market size and forecast, by Application
6.3.4.3. UK
6.3.4.3.1. Market size and forecast, by Type
6.3.4.3.2. Market size and forecast, by Application
6.3.4.4. Rest of Europe
6.3.4.4.1. Market size and forecast, by Type
6.3.4.4.2. Market size and forecast, by Application
6.4. Asia-Pacific
6.4.1. Key market trends, growth factors and opportunities
6.4.2. Market size and forecast, by Type
6.4.3. Market size and forecast, by Application
6.4.4. Market size and forecast, by country
6.4.4.1. Japan
6.4.4.1.1. Market size and forecast, by Type
6.4.4.1.2. Market size and forecast, by Application
6.4.4.2. China
6.4.4.2.1. Market size and forecast, by Type
6.4.4.2.2. Market size and forecast, by Application
6.4.4.3. India
6.4.4.3.1. Market size and forecast, by Type
6.4.4.3.2. Market size and forecast, by Application
6.4.4.4. Australia
6.4.4.4.1. Market size and forecast, by Type
6.4.4.4.2. Market size and forecast, by Application
6.4.4.5. South Korea
6.4.4.5.1. Market size and forecast, by Type
6.4.4.5.2. Market size and forecast, by Application
6.4.4.6. Rest of Asia-Pacific
6.4.4.6.1. Market size and forecast, by Type
6.4.4.6.2. Market size and forecast, by Application
6.5. LAMEA
6.5.1. Key market trends, growth factors and opportunities
6.5.2. Market size and forecast, by Type
6.5.3. Market size and forecast, by Application
6.5.4. Market size and forecast, by country
6.5.4.1. Brazil
6.5.4.1.1. Market size and forecast, by Type
6.5.4.1.2. Market size and forecast, by Application
6.5.4.2. Rest of LAMEA
6.5.4.2.1. Market size and forecast, by Type
6.5.4.2.2. Market size and forecast, by Application
CHAPTER 7: COMPETITIVE LANDSCAPE
7.1. Introduction
7.2. Top winning strategies
7.3. Product mapping of top 10 player
7.4. Competitive dashboard
7.5. Competitive heatmap
7.6. Top player positioning, 2022
CHAPTER 8: COMPANY PROFILES
8.1. Merck & Co., Inc.
8.1.1. Company overview
8.1.2. Key executives
8.1.3. Company snapshot
8.1.4. Operating business segments
8.1.5. Product portfolio
8.1.6. Business performance
8.1.7. Key strategic moves and developments
8.2. AstraZeneca plc
8.2.1. Company overview
8.2.2. Key executives
8.2.3. Company snapshot
8.2.4. Operating business segments
8.2.5. Product portfolio
8.2.6. Business performance
8.2.7. Key strategic moves and developments
8.3. F. Hoffmann-La Roche Ltd.
8.3.1. Company overview
8.3.2. Key executives
8.3.3. Company snapshot
8.3.4. Operating business segments
8.3.5. Product portfolio
8.3.6. Business performance
8.3.7. Key strategic moves and developments
8.4. Merck KGaA
8.4.1. Company overview
8.4.2. Key executives
8.4.3. Company snapshot
8.4.4. Operating business segments
8.4.5. Product portfolio
8.4.6. Business performance
8.4.7. Key strategic moves and developments
8.5. Regeneron Pharmaceuticals, Inc.
8.5.1. Company overview
8.5.2. Key executives
8.5.3. Company snapshot
8.5.4. Operating business segments
8.5.5. Product portfolio
8.5.6. Business performance
8.5.7. Key strategic moves and developments
8.6. Bristol-Myers Squibb Company
8.6.1. Company overview
8.6.2. Key executives
8.6.3. Company snapshot
8.6.4. Operating business segments
8.6.5. Product portfolio
8.6.6. Business performance
8.6.7. Key strategic moves and developments
8.7. BeiGene, Ltd.
8.7.1. Company overview
8.7.2. Key executives
8.7.3. Company snapshot
8.7.4. Operating business segments
8.7.5. Product portfolio
8.7.6. Business performance
8.7.7. Key strategic moves and developments
8.8. Shanghai Junshi Biosciences Co., Ltd.
8.8.1. Company overview
8.8.2. Key executives
8.8.3. Company snapshot
8.8.4. Operating business segments
8.8.5. Product portfolio
8.8.6. Business performance
8.8.7. Key strategic moves and developments
8.9. GlaxoSmithKline plc
8.9.1. Company overview
8.9.2. Key executives
8.9.3. Company snapshot
8.9.4. Operating business segments
8.9.5. Product portfolio
8.9.6. Business performance
8.9.7. Key strategic moves and developments
8.10. Innovent Biologics, Inc.
8.10.1. Company overview
8.10.2. Key executives
8.10.3. Company snapshot
8.10.4. Operating business segments
8.10.5. Product portfolio
8.10.6. Business performance
8.10.7. Key strategic moves and developments
LIST OF TABLES
TABLE 01. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 02. IMMUNE CHECKPOINT INHIBITORS MARKET FOR CTLA-4 INHIBITOR, BY REGION, 2022-2032 ($MILLION)
TABLE 03. IMMUNE CHECKPOINT INHIBITORS MARKET FOR PD-1 INHIBITOR, BY REGION, 2022-2032 ($MILLION)
TABLE 04. IMMUNE CHECKPOINT INHIBITORS MARKET FOR PD-L1 INHIBITOR, BY REGION, 2022-2032 ($MILLION)
TABLE 05. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 06. IMMUNE CHECKPOINT INHIBITORS MARKET FOR LUNG CANCER, BY REGION, 2022-2032 ($MILLION)
TABLE 07. IMMUNE CHECKPOINT INHIBITORS MARKET FOR BLADDER CANCER, BY REGION, 2022-2032 ($MILLION)
TABLE 08. IMMUNE CHECKPOINT INHIBITORS MARKET FOR MELANOMA, BY REGION, 2022-2032 ($MILLION)
TABLE 09. IMMUNE CHECKPOINT INHIBITORS MARKET FOR COLORECTAL CANCER, BY REGION, 2022-2032 ($MILLION)
TABLE 10. IMMUNE CHECKPOINT INHIBITORS MARKET FOR HODGKIN LYMPHOMA, BY REGION, 2022-2032 ($MILLION)
TABLE 11. IMMUNE CHECKPOINT INHIBITORS MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
TABLE 12. IMMUNE CHECKPOINT INHIBITORS MARKET, BY REGION, 2022-2032 ($MILLION)
TABLE 13. NORTH AMERICA IMMUNE CHECKPOINT INHIBITORS MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 14. NORTH AMERICA IMMUNE CHECKPOINT INHIBITORS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 15. NORTH AMERICA IMMUNE CHECKPOINT INHIBITORS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 16. U.S. IMMUNE CHECKPOINT INHIBITORS MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 17. U.S. IMMUNE CHECKPOINT INHIBITORS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 18. CANADA IMMUNE CHECKPOINT INHIBITORS MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 19. CANADA IMMUNE CHECKPOINT INHIBITORS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 20. MEXICO IMMUNE CHECKPOINT INHIBITORS MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 21. MEXICO IMMUNE CHECKPOINT INHIBITORS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 22. EUROPE IMMUNE CHECKPOINT INHIBITORS MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 23. EUROPE IMMUNE CHECKPOINT INHIBITORS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 24. EUROPE IMMUNE CHECKPOINT INHIBITORS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 25. GERMANY IMMUNE CHECKPOINT INHIBITORS MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 26. GERMANY IMMUNE CHECKPOINT INHIBITORS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 27. FRANCE IMMUNE CHECKPOINT INHIBITORS MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 28. FRANCE IMMUNE CHECKPOINT INHIBITORS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 29. UK IMMUNE CHECKPOINT INHIBITORS MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 30. UK IMMUNE CHECKPOINT INHIBITORS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 31. REST OF EUROPE IMMUNE CHECKPOINT INHIBITORS MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 32. REST OF EUROPE IMMUNE CHECKPOINT INHIBITORS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 33. ASIA-PACIFIC IMMUNE CHECKPOINT INHIBITORS MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 34. ASIA-PACIFIC IMMUNE CHECKPOINT INHIBITORS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 35. ASIA-PACIFIC IMMUNE CHECKPOINT INHIBITORS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 36. JAPAN IMMUNE CHECKPOINT INHIBITORS MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 37. JAPAN IMMUNE CHECKPOINT INHIBITORS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 38. CHINA IMMUNE CHECKPOINT INHIBITORS MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 39. CHINA IMMUNE CHECKPOINT INHIBITORS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 40. INDIA IMMUNE CHECKPOINT INHIBITORS MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 41. INDIA IMMUNE CHECKPOINT INHIBITORS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 42. AUSTRALIA IMMUNE CHECKPOINT INHIBITORS MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 43. AUSTRALIA IMMUNE CHECKPOINT INHIBITORS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 44. SOUTH KOREA IMMUNE CHECKPOINT INHIBITORS MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 45. SOUTH KOREA IMMUNE CHECKPOINT INHIBITORS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 46. REST OF ASIA-PACIFIC IMMUNE CHECKPOINT INHIBITORS MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 47. REST OF ASIA-PACIFIC IMMUNE CHECKPOINT INHIBITORS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 48. LAMEA IMMUNE CHECKPOINT INHIBITORS MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 49. LAMEA IMMUNE CHECKPOINT INHIBITORS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 50. LAMEA IMMUNE CHECKPOINT INHIBITORS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 51. BRAZIL IMMUNE CHECKPOINT INHIBITORS MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 52. BRAZIL IMMUNE CHECKPOINT INHIBITORS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 53. REST OF LAMEA IMMUNE CHECKPOINT INHIBITORS MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 54. REST OF LAMEA IMMUNE CHECKPOINT INHIBITORS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 55. MERCK & CO., INC.: KEY EXECUTIVES
TABLE 56. MERCK & CO., INC.: COMPANY SNAPSHOT
TABLE 57. MERCK & CO., INC.: PRODUCT SEGMENTS
TABLE 58. MERCK & CO., INC.: PRODUCT PORTFOLIO
TABLE 59. MERCK & CO., INC.: KEY STRATERGIES
TABLE 60. ASTRAZENECA PLC: KEY EXECUTIVES
TABLE 61. ASTRAZENECA PLC: COMPANY SNAPSHOT
TABLE 62. ASTRAZENECA PLC: PRODUCT SEGMENTS
TABLE 63. ASTRAZENECA PLC: PRODUCT PORTFOLIO
TABLE 64. ASTRAZENECA PLC: KEY STRATERGIES
TABLE 65. F. HOFFMANN-LA ROCHE LTD.: KEY EXECUTIVES
TABLE 66. F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT
TABLE 67. F. HOFFMANN-LA ROCHE LTD.: PRODUCT SEGMENTS
TABLE 68. F. HOFFMANN-LA ROCHE LTD.: PRODUCT PORTFOLIO
TABLE 69. F. HOFFMANN-LA ROCHE LTD.: KEY STRATERGIES
TABLE 70. MERCK KGAA: KEY EXECUTIVES
TABLE 71. MERCK KGAA: COMPANY SNAPSHOT
TABLE 72. MERCK KGAA: PRODUCT SEGMENTS
TABLE 73. MERCK KGAA: PRODUCT PORTFOLIO
TABLE 74. MERCK KGAA: KEY STRATERGIES
TABLE 75. REGENERON PHARMACEUTICALS, INC.: KEY EXECUTIVES
TABLE 76. REGENERON PHARMACEUTICALS, INC.: COMPANY SNAPSHOT
TABLE 77. REGENERON PHARMACEUTICALS, INC.: PRODUCT SEGMENTS
TABLE 78. REGENERON PHARMACEUTICALS, INC.: PRODUCT PORTFOLIO
TABLE 79. REGENERON PHARMACEUTICALS, INC.: KEY STRATERGIES
TABLE 80. BRISTOL-MYERS SQUIBB COMPANY: KEY EXECUTIVES
TABLE 81. BRISTOL-MYERS SQUIBB COMPANY: COMPANY SNAPSHOT
TABLE 82. BRISTOL-MYERS SQUIBB COMPANY: PRODUCT SEGMENTS
TABLE 83. BRISTOL-MYERS SQUIBB COMPANY: PRODUCT PORTFOLIO
TABLE 84. BRISTOL-MYERS SQUIBB COMPANY: KEY STRATERGIES
TABLE 85. BEIGENE, LTD.: KEY EXECUTIVES
TABLE 86. BEIGENE, LTD.: COMPANY SNAPSHOT
TABLE 87. BEIGENE, LTD.: PRODUCT SEGMENTS
TABLE 88. BEIGENE, LTD.: PRODUCT PORTFOLIO
TABLE 89. BEIGENE, LTD.: KEY STRATERGIES
TABLE 90. SHANGHAI JUNSHI BIOSCIENCES CO., LTD.: KEY EXECUTIVES
TABLE 91. SHANGHAI JUNSHI BIOSCIENCES CO., LTD.: COMPANY SNAPSHOT
TABLE 92. SHANGHAI JUNSHI BIOSCIENCES CO., LTD.: PRODUCT SEGMENTS
TABLE 93. SHANGHAI JUNSHI BIOSCIENCES CO., LTD.: PRODUCT PORTFOLIO
TABLE 94. SHANGHAI JUNSHI BIOSCIENCES CO., LTD.: KEY STRATERGIES
TABLE 95. GLAXOSMITHKLINE PLC: KEY EXECUTIVES
TABLE 96. GLAXOSMITHKLINE PLC: COMPANY SNAPSHOT
TABLE 97. GLAXOSMITHKLINE PLC: PRODUCT SEGMENTS
TABLE 98. GLAXOSMITHKLINE PLC: PRODUCT PORTFOLIO
TABLE 99. GLAXOSMITHKLINE PLC: KEY STRATERGIES
TABLE 100. INNOVENT BIOLOGICS, INC.: KEY EXECUTIVES
TABLE 101. INNOVENT BIOLOGICS, INC.: COMPANY SNAPSHOT
TABLE 102. INNOVENT BIOLOGICS, INC.: PRODUCT SEGMENTS
TABLE 103. INNOVENT BIOLOGICS, INC.: PRODUCT PORTFOLIO
TABLE 104. INNOVENT BIOLOGICS, INC.: KEY STRATERGIES
LIST OF FIGURES
FIGURE 01. IMMUNE CHECKPOINT INHIBITORS MARKET, 2022-2032
FIGURE 02. SEGMENTATION OF IMMUNE CHECKPOINT INHIBITORS MARKET,2022-2032
FIGURE 03. TOP IMPACTING FACTORS IN IMMUNE CHECKPOINT INHIBITORS MARKET (2022 TO 2032)
FIGURE 04. TOP INVESTMENT POCKETS IN IMMUNE CHECKPOINT INHIBITORS MARKET (2023-2032)
FIGURE 05. HIGH BARGAINING POWER OF SUPPLIERS
FIGURE 06. MODERATE THREAT OF NEW ENTRANTS
FIGURE 07. LOW THREAT OF SUBSTITUTES
FIGURE 08. LOW INTENSITY OF RIVALRY
FIGURE 09. HIGH BARGAINING POWER OF BUYERS
FIGURE 10. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
FIGURE 11. IMMUNE CHECKPOINT INHIBITORS MARKET, BY TYPE, 2022 AND 2032(%)
FIGURE 12. COMPARATIVE SHARE ANALYSIS OF IMMUNE CHECKPOINT INHIBITORS MARKET FOR CTLA-4 INHIBITOR, BY COUNTRY 2022 AND 2032(%)
FIGURE 13. COMPARATIVE SHARE ANALYSIS OF IMMUNE CHECKPOINT INHIBITORS MARKET FOR PD-1 INHIBITOR, BY COUNTRY 2022 AND 2032(%)
FIGURE 14. COMPARATIVE SHARE ANALYSIS OF IMMUNE CHECKPOINT INHIBITORS MARKET FOR PD-L1 INHIBITOR, BY COUNTRY 2022 AND 2032(%)
FIGURE 15. IMMUNE CHECKPOINT INHIBITORS MARKET, BY APPLICATION, 2022 AND 2032(%)
FIGURE 16. COMPARATIVE SHARE ANALYSIS OF IMMUNE CHECKPOINT INHIBITORS MARKET FOR LUNG CANCER, BY COUNTRY 2022 AND 2032(%)
FIGURE 17. COMPARATIVE SHARE ANALYSIS OF IMMUNE CHECKPOINT INHIBITORS MARKET FOR BLADDER CANCER, BY COUNTRY 2022 AND 2032(%)
FIGURE 18. COMPARATIVE SHARE ANALYSIS OF IMMUNE CHECKPOINT INHIBITORS MARKET FOR MELANOMA, BY COUNTRY 2022 AND 2032(%)
FIGURE 19. COMPARATIVE SHARE ANALYSIS OF IMMUNE CHECKPOINT INHIBITORS MARKET FOR COLORECTAL CANCER, BY COUNTRY 2022 AND 2032(%)
FIGURE 20. COMPARATIVE SHARE ANALYSIS OF IMMUNE CHECKPOINT INHIBITORS MARKET FOR HODGKIN LYMPHOMA, BY COUNTRY 2022 AND 2032(%)
FIGURE 21. COMPARATIVE SHARE ANALYSIS OF IMMUNE CHECKPOINT INHIBITORS MARKET FOR OTHERS, BY COUNTRY 2022 AND 2032(%)
FIGURE 22. IMMUNE CHECKPOINT INHIBITORS MARKET BY REGION, 2022 AND 2032(%)
FIGURE 23. U.S. IMMUNE CHECKPOINT INHIBITORS MARKET, 2022-2032 ($MILLION)
FIGURE 24. CANADA IMMUNE CHECKPOINT INHIBITORS MARKET, 2022-2032 ($MILLION)
FIGURE 25. MEXICO IMMUNE CHECKPOINT INHIBITORS MARKET, 2022-2032 ($MILLION)
FIGURE 26. GERMANY IMMUNE CHECKPOINT INHIBITORS MARKET, 2022-2032 ($MILLION)
FIGURE 27. FRANCE IMMUNE CHECKPOINT INHIBITORS MARKET, 2022-2032 ($MILLION)
FIGURE 28. UK IMMUNE CHECKPOINT INHIBITORS MARKET, 2022-2032 ($MILLION)
FIGURE 29. REST OF EUROPE IMMUNE CHECKPOINT INHIBITORS MARKET, 2022-2032 ($MILLION)
FIGURE 30. JAPAN IMMUNE CHECKPOINT INHIBITORS MARKET, 2022-2032 ($MILLION)
FIGURE 31. CHINA IMMUNE CHECKPOINT INHIBITORS MARKET, 2022-2032 ($MILLION)
FIGURE 32. INDIA IMMUNE CHECKPOINT INHIBITORS MARKET, 2022-2032 ($MILLION)
FIGURE 33. AUSTRALIA IMMUNE CHECKPOINT INHIBITORS MARKET, 2022-2032 ($MILLION)
FIGURE 34. SOUTH KOREA IMMUNE CHECKPOINT INHIBITORS MARKET, 2022-2032 ($MILLION)
FIGURE 35. REST OF ASIA-PACIFIC IMMUNE CHECKPOINT INHIBITORS MARKET, 2022-2032 ($MILLION)
FIGURE 36. BRAZIL IMMUNE CHECKPOINT INHIBITORS MARKET, 2022-2032 ($MILLION)
FIGURE 37. REST OF LAMEA IMMUNE CHECKPOINT INHIBITORS MARKET, 2022-2032 ($MILLION)
FIGURE 38. TOP WINNING STRATEGIES, BY YEAR (2019-2023)
FIGURE 39. TOP WINNING STRATEGIES, BY DEVELOPMENT (2019-2023)
FIGURE 40. TOP WINNING STRATEGIES, BY COMPANY (2019-2023)
FIGURE 41. PRODUCT MAPPING OF TOP 10 PLAYERS
FIGURE 42. COMPETITIVE DASHBOARD
FIGURE 43. COMPETITIVE HEATMAP: IMMUNE CHECKPOINT INHIBITORS MARKET
FIGURE 44. TOP PLAYER POSITIONING, 2022
FIGURE 45. MERCK & CO., INC.: NET REVENUE, 2020-2022 ($MILLION)
FIGURE 46. MERCK & CO., INC.: REVENUE SHARE BY SEGMENT, 2022 (%)
FIGURE 47. MERCK & CO., INC.: REVENUE SHARE BY REGION, 2022 (%)
FIGURE 48. ASTRAZENECA PLC: NET SALES, 2020-2022 ($MILLION)
FIGURE 49. ASTRAZENECA PLC: REVENUE SHARE BY REGION, 2022 (%)
FIGURE 50. F. HOFFMANN-LA ROCHE LTD.: SALES REVENUE, 2020-2022 ($MILLION)
FIGURE 51. F. HOFFMANN-LA ROCHE LTD.: REVENUE SHARE BY SEGMENT, 2022 (%)
FIGURE 52. MERCK KGAA: NET SALES, 2020-2022 ($MILLION)
FIGURE 53. MERCK KGAA: REVENUE SHARE BY SEGMENT, 2022 (%)
FIGURE 54. MERCK KGAA: REVENUE SHARE BY REGION, 2022 (%)
FIGURE 55. REGENERON PHARMACEUTICALS, INC.: NET REVENUE, 2020-2022 ($MILLION)
FIGURE 56. BRISTOL-MYERS SQUIBB COMPANY: NET SALES, 2020-2022 ($MILLION)
FIGURE 57. BRISTOL-MYERS SQUIBB COMPANY: REVENUE SHARE BY REGION, 2022 (%)
FIGURE 58. BEIGENE, LTD.: NET REVENUE, 2020-2022 ($MILLION)
FIGURE 59. BEIGENE, LTD.: REVENUE SHARE BY REGION, 2022 (%)
FIGURE 60. SHANGHAI JUNSHI BIOSCIENCES CO., LTD.: REVENUE SHARE BY REGION, 2022 (%)
FIGURE 61. GLAXOSMITHKLINE PLC: NET SALES, 2020-2022 ($MILLION)
FIGURE 62. GLAXOSMITHKLINE PLC: REVENUE SHARE BY SEGMENT, 2022 (%)
FIGURE 63. GLAXOSMITHKLINE PLC: REVENUE SHARE BY REGION, 2022 (%)
FIGURE 64. INNOVENT BIOLOGICS, INC.: NET REVENUE, 2019-2021 ($MILLION)
FIGURE 65. INNOVENT BIOLOGICS, INC.: REVENUE SHARE BY REGION, 2021 (%)

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings